RNAZ (TransCode Therapeutics) Revenue: $0.00 Mil (TTM As of Mar. 2026)


RNAZ TransCode Therapeutics Inc RNAZ
32 GF Score
Price $7.77
! 1 Warning Sign
View Full Analysis

What is TransCode Therapeutics Revenue?

TransCode Therapeutics RNAZ -9.76% 32 Revenue is $0.00 Mil as of Mar. 2026. GuruFocus rates RNAZ with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

TransCode Therapeutics's revenue for the three months ended in Mar. 2026 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil. TransCode Therapeutics's Revenue per Share for the three months ended in Mar. 2026 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


TransCode Therapeutics  (NAS:RNAZ) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


TransCode Therapeutics Revenue Related Terms


TransCode Therapeutics Revenue Historical Data

* Premium members only.

The historical data trend for TransCode Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransCode Therapeutics Revenue Chart

TransCode Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

TransCode Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RNAZ vs ENSC, ALZN, CELZ: Revenue Comparison

For the Biotechnology subindustry, TransCode Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TransCode Therapeutics Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TransCode Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where TransCode Therapeutics's Revenue falls into.


RNAZ
32GF Score
TransCode Therapeutics Inc RNAZ
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransCode Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $0.00 Mil mean?
TransCode Therapeutics (RNAZ) has a Revenue of $0.00 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on TransCode Therapeutics and its competitors.
Is TransCode Therapeutics' Revenue too high?
TransCode Therapeutics' current Revenue is $0.00 Mil. Overall, TransCode Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does TransCode Therapeutics' Revenue compare to ENSC and ALZN?
TransCode Therapeutics' Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on TransCode Therapeutics and its competitors. TransCode Therapeutics's current Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransCode Therapeutics stock overvalued right now?
TransCode Therapeutics (RNAZ) has a current Revenue of $0.00 Mil. The current Revenue is $0.00 Mil. TransCode Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For TransCode Therapeutics (RNAZ), the current Revenue is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TransCode Therapeutics Business Description

Address 6 Liberty Square, No. 2382, Boston, MA, USA, 02109
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
32GF Score

Get the complete analysis for RNAZ

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.77
Price